Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities
Net income (loss) including redeemable non-controlling interests	$ 932	$ 117	$ (565)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	747	561	509
Stock-based compensation	1,051	1,099	1,088
Reduction of operating lease right-of-use assets and accretion of operating lease liabilities	118	103	108
Amortization of deferred contract costs	77	60	45
Office lease impairment expenses	11	83	0
Adjustments to non-marketable equity securities, including impairment, net	(17)	4	101
Other	37	(31)	(30)
Changes in assets and liabilities, net of assets acquired and liabilities assumed from acquisitions:
Funds held at payment processors	(113)	(87)	86
Accounts receivable, net	(359)	(222)	(141)
Prepaid expenses and other current assets	(247)	(146)	(105)
Other assets	(240)	(279)	(96)
Accounts payable	54	82	70
Accrued expenses and other current liabilities	577	943	702
Payments for operating lease liabilities	(125)	(116)	(113)
Other liabilities	(72)	(39)	14
Net cash provided by operating activities	2,431	2,132	1,673
Cash flows from investing activities
Purchases of property and equipment	(257)	(104)	(123)
Capitalized software and website development costs	(348)	(226)	(201)
Purchases of investments	(1,376)	(1,951)	(1,946)
Maturities of investments	1,379	1,774	1,940
Sales of investments	433	70	7
Purchases of non-marketable investments	(47)	0	(17)
Acquisitions, net of cash acquired	(4,151)	0	0
Settlement of deal-contingent forward contract	(24)	0	0
Other investing activities	0	(7)	(2)
Net cash used in investing activities	(4,391)	(444)	(342)
Cash flows from financing activities
Proceeds from issuance of convertible notes, net of issuance costs	2,720	0	0
Proceeds from issuance of warrants	341	0	0
Purchase of convertible note hedges	(680)	0	0
Proceeds from exercise of stock options	9	14	6
Repurchase of common stock	0	(224)	(750)
Payments of acquisition-related deferred cash consideration	(20)	0	0
Other financing activities	(10)	6	(8)
Net cash provided by (used in) financing activities	2,360	(204)	(752)
Foreign currency effect on cash and cash equivalents, and restricted cash and cash equivalents	60	(35)	5
Net increase in cash and cash equivalents, and restricted cash and cash equivalents	460	1,449	584
Beginning of period	4,221	2,772	2,188
End of period	$ 4,681	$ 4,221	$ 2,772